Drug Profile
ECCS 50
Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Plus Therapeutics; Adipose-derived stem cells - Plus Therapeutics; ADRCs - Plus Therapeutics; Cytori Cell Therapy; ECCI-50; ECCO-50; ECCS-50; Habeo; Habeo Cell TherapyLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Cytori Therapeutics
- Developer Aix-Marseille University; Assistance Publique - Hopitaux de Marseille; Nagoya University; Plus Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Scleroderma
- No development reported Crohn's disease; Scars; Urinary incontinence
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in France (Parenteral)
- 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Scars in Unknown
- 06 Apr 2021 No development reported - Phase-III for Urinary incontinence in Japan (Transurethral)